| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT00004058 | Chronic Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Myelodysplastic/Myeloproliferative Diseases|Precancerous/Nonmalignant Condition | Drug: tetradecanoylphorbol acetate | University of Medicine and Dentistry of New Jersey|National Cancer Institute (NCI)|Rutgers, The State University of New Jersey | Phase 1 | 1998-12-01 | 2010-01-25 |
| NCT01009931 | Leukemia | Drug: 12-O-tetradecanoylphorbol-13-acetate|Drug: Dexamethasone|Drug: Choline magnesium trisalicylate | Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|Biosuccess Biotech Co., Ltd. | Phase 2 | 2011-03-01 | 2015-11-02 |
| NCT00204789 | Post-solid Organ Transplant|Skin Neoplasms | Drug: Difluoromethylornithine | University of Wisconsin, Madison | Phase 2 | 2003-07-01 | 2015-09-30 |
| NCT01850459 | Autism Spectrum Disorders | Children's Hospital Medical Center, Cincinnati | | 2013-01-01 | 2014-03-05 |
